Olimel N12e (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

Olimel N12e is employed in parenteral nutrition to provide a balanced amino acid profile for patients who cannot receive enteral feeding or who are in a catabolic state.

• Parenteral nutrition for patients unable to receive enteral feeding: delivers essential and non‑essential amino acids to meet protein and nitrogen requirements.
• Critical care and postoperative patients requiring amino acid supplementation: supports tissue repair and prevents muscle loss during intensive care.
• Support of protein synthesis in catabolic states: helps maintain lean body mass and immune function during illness or injury.

• Each amino acid in Olimel N12e serves as a substrate for protein synthesis, contributing to the restoration of nitrogen balance and the production of new tissue proteins. By supplying both essential and non‑essential amino acids directly into the bloodstream, the solution bypasses gastrointestinal absorption, allowing rapid availability for cellular uptake, metabolic pathways, and the synthesis of enzymes, hormones, and immune mediators.

Intravenous administration of amino acid solutions may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Hyperglycemia: elevated blood glucose levels, especially in diabetic patients.
• Electrolyte disturbances: shifts in potassium, sodium, or calcium concentrations.
• Infusion site reactions: erythema, pain, or phlebitis at the catheter site.
• Nausea or vomiting: gastrointestinal discomfort during or after infusion.

Serious or Rare Side Effects

• Anaphylactic reaction: severe hypersensitivity requiring immediate medical intervention.
• Severe hyperammonemia: excessive ammonia accumulation leading to neurologic symptoms.
• Hepatic dysfunction: liver enzyme elevations indicating possible liver stress.
• Renal impairment: worsening kidney function due to nitrogen load.

When using Olimel N12e, clinicians should observe several safety considerations to minimize risks.

• Monitor blood glucose: adjust insulin therapy as needed during infusion.
• Assess electrolyte levels: regularly check serum potassium, sodium, and calcium.
• Evaluate renal function: avoid or limit use in patients with severe renal insufficiency.
• Screen for inborn errors of metabolism: contraindicated in phenylketonuria, maple‑sweet urine disease, or other amino‑acid disorders.
• Use aseptic technique: ensure sterile handling to prevent catheter‑related infections.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Amino acid solutions can interact with other therapies, influencing metabolic balance or increasing adverse event risk.

Major Interactions (Avoid)

• Inborn errors of amino‑acid metabolism (e.g., phenylketonuria, maple‑sweet urine disease): risk of toxic metabolite accumulation.
• Severe renal failure: excessive nitrogen load may worsen uremia.
• High‑protein enteral nutrition administered concurrently: may cause nitrogen overload.

Moderate Interactions (Monitor Closely)

• Insulin or oral hypoglycemic agents: may require dose adjustment due to glucose changes.
• Electrolyte‑containing IV fluids: monitor for additive electrolyte shifts.
• Loop diuretics: watch for volume depletion and electrolyte imbalance.